Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting

Clinical Cardiology

Volumn 21, Issue 2, 1998, Pages 103-108

  Philbin, Edward F ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Congestive heart failure; Diastole

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ANAMNESIS; ARTICLE; COMMUNITY CARE; CONGESTIVE HEART FAILURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRESCRIPTION; PREVALENCE; STATISTICAL ANALYSIS;

EID: 0031938750     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960210208     Document Type: Article

References (35)

1. Captopril Multicenter Research Group: A placebo-controlled trial of refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-763
2. Packer M, Lee WH, Yushak M, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847-853
3. Kjekshus J, Swedberg K: Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988:62:67A-72A
4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
6. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT: Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1994;23:393-400
7. Cohn JN, Johnson G, Zieshe S, Cobb F, Francis G, Tritsani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
8. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677
9. Paul SD, Kuntz KM, Eagle KA, Weinstein NC: Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-1149
10. Konstam MA, Dracup K, Bottoroff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF: Quick Reference Guide for Clinicians No. 11: Heart Failure: Management of Patients with Left Ventricular Systolic Dysfunction. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services, AHCPR Publication No. 94-0613, 1994
11. Johnstone DE, Abdulla A, Arnold JMO, Bernstein V, Bourassa M, Brophy J, Davies R, Gardner M, Hoeschen R, Mickleborough L, Moe G, Montague T, Paquet M, Rouleau JL, Yusuf S: Diagnosis and management of heart failure. Can J Cardiol 1994;10:613-631
12. Rajfer SI: Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993;22(suppl A):198A-200A
13. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994;13:S107-112
14. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL: Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-838
15. Stafford RS, Saglam D, Blumenthal D: Low rates of angiotensin-converting enzyme inhibitor use in congestive heart failure (abstr). Circulation 1996;94(suppl I):I-94
16. Shah N, Edep M, Massie BM: Differences between cardiologists and heart failure specialists in the management of congestive heart failure (abstr). Circulation 1995;92(suppl I):I-666
17. Philbin EF, Lynch LJ, Rocco TA, Lindenmuth NW, Ulrich K, McCall M, Roerden JB, Jenkins P: Does quality improvement work? The Management to Improve Survival in Congestive Heart Failure (MISCHF) Study. Jt Comm J Qual Improv 1996;22:721-733
18. 3M Health Information Services, U.S. Health Care Financing Administration: Diagnosis Related Groups Definitions Manual. Wallingford, Conn.: 3M Health Information Services, 1993
19. 3M Health Information Services, New York State Department of Health Division of Health Care Financing: All Patient Diagnosis Related Groups Definitions Manual. Wallingford, Conn.: 3M Health Information Services, 1993
20. Mohan P, Hii JT, Wuttke RD, Esterman AJ, Hollington P, Horowitz JD: Acute heart failure: Determinants of outcome. Int J Cardiol 1991;32:365-376
21. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87(suppl VI):VI-5-VI-16
22. Franciosa JA: Why patients with heart failure die: Hemodynamic and functional determinants of survival. Circulation 1987;75(suppl IV):IV-20-IV27
23. Gradman AH, Deedwania PC: Predictors of mortality in patients with heart failure. Cardiol Clinics 1994;12(1):25-35
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373-383
25. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive heart failure: Mechanisms and management. Ann Intern Med 1992;117:502-510
26. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure. J Am Coll Cardiol 1995;26:1565-1574
27. Philbin EF, Rocco TA: The utility of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134:188-195
28. Suki WN: Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989;149:669-673
29. Oster JR, Materson BJ: Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992;152:704-710
30. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tritsani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552
31. Packer M, Kessler PD, Lee WH: Calcium-channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation 1987;75(suppl V):V56-V64
32. Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ: Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996;335:1198-1205
33. Williams JF, Bristow MR, Fowler MB, Francis GS, Garson A, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters WL: Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-2784
34. Blumenthal D: Quality of health care. Part 1: Quality of care - what is it? N Engl J Med 1996;335:891-893
35. West JA, Miller NH, Parker KM, Senneca D, Ghandour G, Clark M, Greenwald G, Heller RS, Fowler MB, DeBusk RF: A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997;79:58-63